Wenxiu Yao

2.4k total citations
39 papers, 729 citations indexed

About

Wenxiu Yao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Wenxiu Yao has authored 39 papers receiving a total of 729 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Wenxiu Yao's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Wenxiu Yao is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (12 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Wenxiu Yao collaborates with scholars based in China, United States and Spain. Wenxiu Yao's co-authors include Xiaobo Du, Lijuan Chen, Zhujuan Xiong, Guangli Yang, Xia Zhao, Bin Ye, Wei Zhang, Yuquan Wei, Minghai Tang and Linyu Fan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Wenxiu Yao

39 papers receiving 719 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wenxiu Yao China 12 327 232 129 91 80 39 729
Kobra Velaei Iran 14 400 1.2× 202 0.9× 88 0.7× 159 1.7× 59 0.7× 20 827
Yasushi Ohno Japan 19 326 1.0× 135 0.6× 259 2.0× 83 0.9× 88 1.1× 61 1.0k
Vanessa Jacob Victorino Brazil 19 357 1.1× 255 1.1× 59 0.5× 159 1.7× 68 0.8× 34 950
E. Planchat France 8 326 1.0× 233 1.0× 86 0.7× 108 1.2× 28 0.3× 16 676
Dipita Bhakta-Guha India 10 376 1.1× 209 0.9× 62 0.5× 109 1.2× 33 0.4× 18 761
Rhonda J. Rosengren New Zealand 16 470 1.4× 187 0.8× 91 0.7× 139 1.5× 56 0.7× 32 943
Xiaoran Yin China 16 428 1.3× 95 0.4× 69 0.5× 208 2.3× 50 0.6× 28 854
Chien‐shan Cheng China 19 576 1.8× 317 1.4× 149 1.2× 269 3.0× 34 0.4× 63 1.2k
Takenori Takahata Japan 19 477 1.5× 377 1.6× 95 0.7× 161 1.8× 29 0.4× 50 1.3k

Countries citing papers authored by Wenxiu Yao

Since Specialization
Citations

This map shows the geographic impact of Wenxiu Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenxiu Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenxiu Yao more than expected).

Fields of papers citing papers by Wenxiu Yao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenxiu Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenxiu Yao. The network helps show where Wenxiu Yao may publish in the future.

Co-authorship network of co-authors of Wenxiu Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Wenxiu Yao. A scholar is included among the top collaborators of Wenxiu Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenxiu Yao. Wenxiu Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ai, Xinghao, Yunyan Zhang, Tongmei Zhang, et al.. (2025). A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced small cell lung cancer.. Journal of Clinical Oncology. 43(16_suppl). 8007–8007. 2 indexed citations
3.
Mok, Tony, Wenxiu Yao, M. Duruisseaux, et al.. (2024). KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.. Journal of Clinical Oncology. 42(17_suppl). LBA8509–LBA8509. 39 indexed citations
4.
Dong, Xiaorong, Jianhua Chen, Yan Yu, et al.. (2023). Phase 1b study of HS-10241 combined with almonertinib in pre-treated advanced non-small cell lung cancer (NSCLC) harboring EGFR mutation.. Journal of Clinical Oncology. 41(16_suppl). e21134–e21134. 1 indexed citations
5.
6.
Li, Juan, et al.. (2021). ALK-positive histiocytosis with disseminated disease responded to alectinib: a case report. Annals of Palliative Medicine. 10(9). 10095–10101. 11 indexed citations
7.
8.
Li, Xin, et al.. (2021). A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors. Translational Cancer Research. 10(2). 1119–1130. 9 indexed citations
9.
Wang, Ke, Juan Li, Jianguo Sun, et al.. (2021). [Recommendations from Experts in the Management of Adverse Reactions 
to ALK Inhibitors (2021 Version)].. SHILAP Revista de lepidopterología. 24(12). 815–828. 2 indexed citations
10.
Yao, Wenxiu, Liyang Wang, Huan Huang, et al.. (2020). All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells. BMC Cancer. 20(1). 315–315. 38 indexed citations
11.
Wang, Liyang, Hua Xie, Hang Zhou, et al.. (2017). Efficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. Saudi Medical Journal. 38(1). 18–23. 6 indexed citations
12.
Li, Fang, et al.. (2017). Investigation of the anti-cancer effect of quercetin on HepG2 cells in vivo. PLoS ONE. 12(3). e0172838–e0172838. 68 indexed citations
13.
Zhou, Jin, Li Fang, Hua Xie, et al.. (2016). Quercetin reduces cyclin D1 activity and induces G1 phase arrest in HepG2 cells. Oncology Letters. 12(1). 516–522. 32 indexed citations
14.
Zhang, Qiongwen, Chunhua Yu, Shijian Feng, et al.. (2015). Physicians' Practice, Attitudes Toward, and Knowledge of Cancer Pain Management in China. Pain Medicine. 16(11). 2195–2203. 34 indexed citations
15.
Chen, Hengyi, Wenxiu Yao, Qian Chu, et al.. (2015). Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer Letters. 369(1). 97–102. 80 indexed citations
16.
Zeng, Chao, Hang Zhou, Wei Yang, et al.. (2014). Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials. Chinese Medical Journal. 127(5). 951–956. 5 indexed citations
17.
Zhou, Hang, et al.. (2013). Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6844 patients. Chinese Medical Journal. 126(17). 3348–3355. 5 indexed citations
18.
Huang, Lili, Lihua Liu, Xiaobo Du, et al.. (2013). Cancer department nurses’ attitudes and practices in response to the sexual issues of pelvic radiation patients: A survey in Sichuan, China. Contemporary Nurse. 43(2). 146–151. 14 indexed citations
19.
Zhou, Hang, Chao Zeng, Yang Wei, Jin Zhou, & Wenxiu Yao. (2013). Duration of Chemotherapy for Small Cell Lung Cancer: A Meta-Analysis. PLoS ONE. 8(8). e73805–e73805. 18 indexed citations
20.
Zhang, Xiaolong, Wei Wen, Wenxiu Yao, et al.. (2011). Clinical management of gastric cancer: results of a multicentre survey. BMC Cancer. 11(1). 369–369. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kobra Velaei Breakdown of academic impact, for papers by Yasushi Ohno Breakdown of academic impact, for papers by Vanessa Jacob Victorino Breakdown of academic impact, for papers by E. Planchat Breakdown of academic impact, for papers by Dipita Bhakta-Guha Breakdown of academic impact, for papers by Rhonda J. Rosengren Breakdown of academic impact, for papers by Xiaoran Yin Breakdown of academic impact, for papers by Chien‐shan Cheng Breakdown of academic impact, for papers by Takenori Takahata
Rankless by CCL
2026